We’re in Amsterdam with Sander van Deventer, the CEO of VectorY. We will talk about VectorY and what’s missing in gene therapy.

💎 ABOUT THE SPEAKER
Sander has an impressive track record, being a professor, operational biotech founder and a VC. In 1998, he co-founded uniQure, which brought the first gene therapy to the market. He also co-founded the leading VC Forbion as well as Dezima. He is now building a new venture VectorY, again in gene therapy. I interviewed him in 2017 back at Labiotech so it’s great to catch up with him again.

📜 TRANSCRIPT
Read the full transcript here: https://flot.bio/episode/sander-van-deventer-gene-therapy/

🫶 FOLLOW US
- Newsletter: http://eepurl.com/h_fnmH
- LinkedIn: https://www.linkedin.com/company/flot-bio/
- X (Twitter): https://x.com/FlotBio

🎙️ ABOUT FLOT.BIO
Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 10k monthly views. Free.

⭐️ SPONSORSHIP
Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!

🙏 LIKE/FOLLOW/REVIEW
Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.

⏰ TIMESTAMPS

[00:00:00 ] Intro
[00:01:54 ] VectorY: Raising the largest Series A in 2023 in 🇪🇺
[00:05:01 ] What's coming for ALS
[00:07:50 ] How Vectorized Antibodies work
[00:17:57 ] New Vector (AAV) technologies
[00:22:55 ] The pipeline of VectorY
[00:27:22 ] Where VC money is moving to
[00:32:29 ] The Netherlands as a biotech cluster
[00:35:31 ] CRISPR approval and gene therapy reimbursement
[00:48:15 ] Where Sander came from
[00:56:14 ] How to have the energy to be a serial entrepreneur